# US 2012/0231011 A1 · Anti-vegf monoclonal antibody and pharmaceutical composition comprising said antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0231011 A1
- Document ID: US20120231011A1
- Status: Published application
- Kind: A1
- Application number: 13/393,185
- Filed: 2010-08-27
- Published: 2012-09-13
- Earliest claimed: 2009-08-28
- Assignees: Apexigen, Inc.; Jiangsu Simcere Pharmaceutical R&D Co., Ltd.
- Inventors: Pierre Li; Yaohuang ke; Yongke Zhang; Weimin Zhu; Guoliang Yu; Fanxin Ma; Xin Fan
- Web page: https://patentgrep.com/patent/US20120231011A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides an anti-VEGF monoclonal antibody, which has the variable region of heavy chain comprising the amino acid sequences of SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3, and/or the variable region of light chain comprising the amino acid sequences of SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6. The antibody can be produced by the cell line with the preservation number of CGMCC NO. 3233. The invention also provides the use of said antibody for the manufacture of medicaments for the treatment of a disease that is relevant to VEGF, wherein further provided are pharmaceutical composition, agents, kits and chips comprising said antibody, as well as the cell line with the preservation number of CGMCC NO. 3233.

## Claims

### Claim 1

A monoclonal antibody, characterized in that the variable domain of heavy chain thereof comprises amino acid sequences of SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3, and/or the variable domain of light chain thereof comprises amino acid sequences of SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6.

### Claim 2 (depends on 1)

The monoclonal antibody as set forth in claim 1, characterized in that said monoclonal antibody comprises single-strand antibody, double-strand antibody, chimeric antibody, humanized antibody, and derivatives, functional equivalents and homologues of the above antibodies, and may further comprises antibody segments and any polypeptide comprising antigen binding domains.

### Claim 3 (depends on 1)

The monoclonal antibody as set forth in claim 1, characterized in that the amino acid sequence of its heavy chain variable domain is shown by SEQ ID NO. 7; or its heavy chain variable domain is derived by substitution, deletion or addition of one or several amino acids of the amino acid sequence shown by SEQ ID NO. 7, has at least 95% identity with SEQ ID NO. 7, and said monoclonal antibody has the activity of specifically binding with VEGF.

### Claim 4 (depends on 1)

The monoclonal antibody as set forth in claim 1, characterized in that the amino acid sequence of its light chain variable domain is shown by SEQ ID NO. 8; or its light chain variable domain is derived by substitution, deletion or addition of one or several amino acids of the amino acid sequence shown by SEQ ID NO. 8, has at least 95% identity with SEQ ID NO. 8, and said monoclonal antibody has the activity of specifically binding with VEGF.

### Claim 5 (depends on 1)

The monoclonal antibody as set forth in claim 1, characterized in that its heavy chain amino acid sequence is shown by SEQ ID NO. 9; or its heavy chain is derived by substitution, deletion or addition of one or several amino acids of the amino acid sequence shown by SEQ ID NO. 9, has at least 95% identity with SEQ ID NO. 9, and said monoclonal antibody has the activity of specifically binding with VEGF.

### Claim 6 (depends on 1)

The monoclonal antibody as set forth in claim 1, characterized in that its light chain amino acid sequence is shown by SEQ ID NO. 10; or its light chain is derived by substitution, deletion or addition of one or several amino acids of the amino acid sequence shown by SEQ ID NO. 10, has at least 95% identity with SEQ ID NO. 10, and said monoclonal antibody has the activity of specifically binding with VEGF.

### Claim 7 (depends on 1)

The monoclonal antibody as set forth in claim 1, characterized in that it is produced by the cell line deposited under the accession number of CGMCC No. 3233.

### Claim 8

A cell line, characterized in that it is deposited in CGMCC under the accession number of CGMCC No. 3233.

### Claim 9 (depends on 1)

A method for treating a VEGF-associated disease, comprising administering to a patient in need thereof an effective amount of the monoclonal antibody as set forth in claim 1.

### Claim 10 (depends on 9)

The method as set forth in claim 9, characterized in that said VEGF-associated diseases is a tumor, age-related macular degeneration (AMD), a neurodegenerative disease, obesity, or diabetes.

### Claim 11 (depends on 1)

A pharmaceutical composition, characterized in that it comprises an effective amount of the monoclonal antibody as set forth in claim 1 and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 1)

A reagent, kit or chip, comprising the monoclonal antibody as set forth in claim 1.
